Sana Klinikum Offenbach GmbH

At Sana Klinikum Offenbach GmbH, a major share of the clinical research focuses on breast cancer within the broader oncology field. Studies are exploring how to improve outcomes for early-stage, high-risk, and metastatic disease, with attention to treatment effectiveness, recurrence prevention, and disease-free survival.

• High-risk HER2-negative and hormone receptor-positive breast cancer
• Triple-negative breast cancer and residual disease after surgery
• Testing new immunotherapy and targeted treatment combinations
• Improving long-term control and reducing relapse risk after standard treatment

These trials aim to refine adjuvant and neoadjuvant therapy, helping identify better options for patients with early and advanced breast cancer.

The site also conducts extensive research in respiratory tract diseases, especially non-small cell lung cancer and small cell lung cancer. The studies are designed to evaluate newer treatment strategies for advanced, metastatic, and unresectable disease, including approaches that combine targeted therapy, chemotherapy, and immunotherapy.

• Advanced non-small cell lung cancer, including KRAS G12C and EGFR-related disease
• Unresectable stage III and stage IV NSCLC
• Limited disease small cell lung cancer
• Assessing response, survival, and treatment tolerability with newer regimens

These investigations support more personalized care for lung cancer, with a focus on improving survival while maintaining manageable treatment burden in patients treated at the Ambulantes Onkologisches Zentrum.

Research in hematologic malignancies at this hospital includes studies in chronic lymphocytic leukemia and related small lymphocytic lymphoma. The trials are centered on finding more effective treatment combinations for patients whose disease has already been treated before.

• Chronic lymphocytic leukemia and small lymphocytic lymphoma
• Evaluating targeted therapies for previously treated disease
• Measuring disease control and progression-free survival
• Exploring safer and more effective options for blood cancers

This work reflects a broader effort to improve outcomes in hematology by testing novel approaches that may extend disease control and support better patient care.

In addition to breast and lung cancer, the site participates in trials across several other solid tumors, including ovarian cancer, rectal cancer, esophageal squamous cell carcinoma, and pleural mesothelioma. These studies are aimed at improving treatment effectiveness and, in some cases, preserving organ function and quality of life.

• Advanced ovarian cancer and treatment response
• Intermediate and high-risk rectal cancer with a focus on organ preservation
• Esophageal squamous cell carcinoma and pleural mesothelioma
• Testing new combinations for broader advanced solid tumor care

Overall, these studies expand the oncology portfolio at Sana Klinikum Offenbach GmbH, covering both common and less frequent cancers while seeking better disease control and more tailored treatment options.